





a**b****c****d**



1 **Supplementary Figure S1 Integrated single-cell reference and derivation of**
2 **malignant transcriptional programmes. a)** Dot plot showing canonical marker-gene
3 expression across broad cell lineages in the single-cell RNA-seq reference. Dot size
4 indicates the percentage of cells expressing each marker and colour indicates scaled
5 average expression. **b)** Stability assessment of consensus NMF solutions across
6 candidate ranks, shown as mean within-cluster cosine similarity. **c)** Pairwise cosine
7 similarity heatmap of the five consensus malignant transcriptional programmes
8 selected for downstream analysis. **d)** Hallmark pathway enrichment of cNMF
9 programmes, with point position showing normalised enrichment score and point size
10 indicating statistical significance.

11 **Supplementary Figure S2 Expression-derived copy-number alteration signal in**
12 **paired biopsy and resection CosMx samples.** infercnvpy heatmaps showing putative
13 large-scale copy-number alteration-like signal inferred from CosMx expression data for
14 paired biopsy and post-treatment resection samples from five OAC cases. Cells are
15 grouped by refined cell annotation and genes are ordered by genomic position across
16 autosomes. Red and blue indicate relative inferred gains and losses, respectively,
17 compared with non-malignant reference populations. These profiles represent
18 transcriptome-derived CNA-like signal and not direct DNA copy-number calls.



BIOPSY

RESECTION



OAC1





OAC2





OAC3









OAC4



OAC5






19 **Supplementary Figure S3 Permutation testing of spatial autocorrelation for**
20 **malignant transcriptional programmes.** Histograms show the permutation-derived
21 null distribution of Moran's I for each cNMF tumour programme in biopsy and resection
22 samples from OAC1–OAC5. Continuous programme scores were analysed across
23 cancer-cell spatial neighbour graphs. Red vertical lines indicate the observed Moran's I
24 statistic, with observed values and permutation P values shown within each panel.
25 Positive observed Moran's I values indicate spatial clustering of malignant programme
26 activity.






27 **Supplementary Figure S4 Spatial mapping of final CosMx cell-type and cancer-**
28 **programme annotations.** Representative CosMx tissue sections showing cell centroid
29 maps coloured by final refined annotation. Labels include malignant cNMF programmes,
30 epithelial states, fibroblast/CAF states, endothelial and mural cells, and immune
31 populations. Spatial maps illustrate the tissue distribution of annotated cell types and
32 malignant transcriptional states across profiled sections.




OAC1






OAC2






OAC3



OAC4




OAC5



33 **Supplementary Figure S5 Selection of spatial niche cluster number.** Sample-level
34 metrics used to select the number of unsupervised spatial niches in each resection
35 sample. For OAC1–OAC5, candidate niche numbers were evaluated using average
36 silhouette width, total within-cluster sum of squares, and clustering stability measured
37 by mean adjusted Rand index. Final niche numbers were selected by balancing
38 separation, stability, parsimony, and biological interpretability.

a



Niche

- 1
- 2
- 3
- 4
- 5

OAC1R

Niche 1

Quiescent fib 1, Quiescent fib 2, Univ. fib, Trans. fib, Stress CAF, DesmoCAF

Niche 2

Cancer, Trans. fib, MyoCAF, M2 Mac, DC

Niche 3

Quiescent fib 2, B cell, Plasma, M1 Mac, Mono, DC, Gran, Endo/mural


Niche 4

Quiescent fib 1, Quiescent fib 2, T cell, Treg, B cell, Plasma, M1 Mac, DC

Niche 5

Quiescent fib 1, Quiescent fib 2, T cell, Treg, NK cell, B cell, Plasma, M1 Mac

b



Niche

- 1
- 2
- 3
- 4
- 5

OAC2R

Niche 1

Quiescent fib 1, Univ. fib, Trans. fib, Basal squam. epi, Cycling basal squam. epi, Diff. squam. epi, Barrett's-like epi, Endo/mural

Niche 2

T cell, Treg, NK cell, B cell, Plasma

Niche 3

Cancer, MyoCAF, M2 Mac


Niche 4

Quiescent fib 1, Quiescent fib 2, DesmoCAF

Niche 5

T cell, NK cell, B cell, Plasma, DC, Gran

c



Niche

- 1
- 2
- 3
- 4
- 5
- 6
- 7

OAC4R

Niche 1

Endo/mural

Niche 2

Univ. fib, Trans. fib, Stress CAF, M1 Mac, M2 Mac, Mono, DC, Gran

Niche 3

Cancer, Quiescent fib 2, Stress CAF, MyoCAF, DesmoCAF, M2 Mac, DC

Niche 4

Basal squam. epi, Cycling basal squam. epi, Diff. squam. epi

Niche 5

M2 Mac, Diff. squam. epi, Barrett's-like epi

Niche 6



Cancer, Quiescent fib 1, T cell, Treg, NK cell, B cell, Plasma, Gran

Niche 7



Cycling basal squam. epi, Diff. squam. epi

39 **Supplementary Figure S6 Spatial localisation and composition of multicellular**
40 **niches.** Spatial maps of unsupervised niche assignments in representative resection
41 samples from **a)** OAC1, **b)** OAC2, and **c)** OAC4. Cells are coloured by niche identity.
42 Summary boxes indicate the dominant or enriched cell types contributing to each niche,
43 including cancer-enriched, fibroblast/CAF-enriched, immune-enriched, epithelial-
44 enriched, and mixed stromal-immune neighbourhoods.



OAC1





OAC2





OAC3



OAC4





OAC5



45 **Supplementary Figure S7 Cancer-centred spatial organisation of fibroblast**
46 **subtypes.** For each resection sample, left panels show the mean percentage of
47 neighbouring cells assigned to each fibroblast subtype at increasing distances from
48 cancer cells. Right panels show empirical cumulative distribution functions for the
49 distance from each fibroblast subtype to the nearest cancer cell. Curves shifted upward
50 at shorter distances indicate closer spatial proximity to malignant epithelium.

51 **Supplementary Figure S8 Abundance-adjusted modelling of fibroblast-immune tri-**
52 **cell niches around cancer cells. a)** Model-estimated differences in the percentage of
53 cancer cells occupying MyoCAF-containing tri-cell niches with each immune subtype,
54 relative to M2 macrophages. Negative values indicate lower adjusted niche frequency
55 compared with M2 macrophage-containing niches. **b)** Adjusted tri-cell niche frequencies
56 for combinations of fibroblast and immune subtypes. Points and horizontal intervals
57 show model-estimated frequencies and uncertainty intervals after adjustment for
58 sample-level cell-type abundance and patient structure.

a**b**Star indicates FDR < 0.1 and $\log_2\text{FC} \geq 0.25$ 

59 **Supplementary Figure S9 Radius sensitivity of MyoCAF–M2 macrophage niche-**
60 **associated cancer-cell transcriptional changes. a)** Mean log₂ fold change of
61 epithelial/glandular and stress/inflammatory gene categories in cancer cells located in
62 a MyoCAF–M2 macrophage niche versus cancer cells lacking nearby MyoCAFs and M2
63 macrophages, across niche radii. Results are shown separately for each malignant
64 cNMF programme. **b)** Heatmap of niche-associated log₂ fold changes for selected
65 epithelial/glandular, stress/inflammatory, and CAF/M2-conditioned genes across
66 neighbourhood radii and tumour programmes. Markers indicate genes meeting the
67 exploratory significance threshold of FDR < 0.1 and absolute log₂ fold change ≥ 0.25.